Imiquimod (maleaat) (Standaard)

Imiquimod (maleate) (Standard) is the analytical standard of Imiquimod (maleate) . This product is intended for research and analytical applications. Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo. Imiquimod maleate can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

896106-16-4

12352100

Autophagy; HSV; Reference Standards; SARS-CoV; Toll-like Receptor (TLR)

Anti-infection; Autophagy; Immunology/Inflammation; Others

Cancer; Infection; Inflammation/Immunology

NC1=NC2=CC=CC=C2C3=C1N=CN3CC(C)C.O=C(O)/C=C\C(O)=O

C18H20N4O4

356.38

[1]Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.|[2]Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6 (6) :554-60.|[3]Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86 (19) :10338-46.|[4]Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126 (6) :1338-47.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B0180BR/

Reference Standards